ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Dec 2017 07:00 AM
RNS
ReNeuron opens US office
13 Nov 2017 11:30 AM
RNS
Notification of Interim Results
08 Nov 2017 07:00 AM
RNS
Retinal disease clinical trial moves into Phase II
31 Oct 2017 07:00 AM
RNS
Positive stroke clinical data & regulatory update
27 Oct 2017 07:00 AM
RNS
Wins further UK grant
11 Oct 2017 01:31 PM
RNS
PDMR Interest in Shares and Share Options
09 Oct 2017 07:00 AM
RNS
Presentation of positive pre-clinical data
12 Sep 2017 07:00 AM
RNS
Directors' Interest in Shares and Share Options
06 Sep 2017 11:15 AM
RNS
Result of AGM
06 Sep 2017 07:00 AM
RNS
AGM Trading Update
01 Sep 2017 07:00 AM
RNS
Non-executive Director Appointment
01 Sep 2017 07:00 AM
RNS
Block Listing Review and TVR
07 Aug 2017 03:04 PM
RNS
Posting of Annual Report and Notice of AGM
04 Aug 2017 04:40 PM
RNS
Second Price Monitoring Extn
04 Aug 2017 04:35 PM
RNS
Price Monitoring Extension
25 Jul 2017 07:00 AM
RNS
Appointment of joint broker
19 Jul 2017 07:00 AM
RNS
Board change
29 Jun 2017 07:00 AM
RNS
Preliminary Results
19 Jun 2017 07:00 AM
RNS
FDA approves cryopreserved hRPC formulation
08 Jun 2017 07:00 AM
RNS
Notification of Preliminary Results
05 Jun 2017 07:00 AM
RNS
Positive FDA feedback on proposed Phase III study
18 May 2017 07:00 AM
RNS
Presents positive exosome data at major conference
11 May 2017 07:00 AM
RNS
Awarded major UK cell therapy manufacturing grant
05 May 2017 07:00 AM
RNS
Presents new exosome data at major conference
21 Apr 2017 07:01 AM
RNS
Update on clinical strategy in stroke disability
21 Apr 2017 07:00 AM
RNS
Update on progress in ophthalmology programmes
01 Mar 2017 07:00 AM
RNS
Block Listing Review and Total Voting Rights
15 Feb 2017 07:00 AM
RNS
ReNeuron featured in BBC documentary
07 Feb 2017 12:32 PM
RNS
Director Share Purchase
14 Dec 2016 12:15 PM
RNS
Director Share Purchase
05 Dec 2016 07:00 AM
RNS
Interim Results
05 Dec 2016 07:00 AM
RNS
Reports Positive Results in Phase II Stroke Trial
14 Nov 2016 07:00 AM
RNS
Notification of Interim Results
05 Oct 2016 02:30 PM
RNS
Notification of Major Interest in Shares
22 Sep 2016 01:00 PM
RNS
Block Listing Review and Total Voting Rights
06 Sep 2016 12:00 PM
RNS
Result of AGM
06 Sep 2016 07:00 AM
RNS
AGM Trading Update
05 Aug 2016 04:35 PM
RNS
Posting of Annual Report and Notice of AGM
04 Aug 2016 07:00 AM
RNS
Stroke clinical data published in The Lancet
22 Jul 2016 07:00 AM
RNS
Publication of positive pre-clinical retinal data
20 Jul 2016 02:31 PM
RNS
Directors' Interest in Shares and Share Options
07 Jul 2016 07:00 AM
RNS
Preliminary Results
14 Jun 2016 07:00 AM
RNS
Notification of Preliminary Results
13 Jun 2016 07:00 AM
RNS
Patient recruitment completed in stroke trial
09 Jun 2016 07:01 AM
RNS
Pursues brain cancer with exosome platform
08 Jun 2016 07:00 AM
RNS
Retinitis pigmentosa update & Notice of KOL event
31 May 2016 12:45 PM
RNS
Change of Adviser
15 Mar 2016 07:00 AM
RNS
First Patient Treated in RP Clinical Trial
23 Feb 2016 07:00 AM
RNS
ReNeuron Relocates to South Wales
17 Feb 2016 04:57 PM
RNS
Director's Dealings

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings